Dr. Daniel Egan, MD
Claim this profileSwedish Cancer Institute
Studies Acute Myeloid Leukemia
Studies Leukemia
6 reported clinical trials
7 drugs studied
Area of expertise
1Acute Myeloid Leukemia
Stage II
Stage I
2Leukemia
Stage II
Stage I
Affiliated Hospitals
Clinical Trials Daniel Egan, MD is currently running
APG-2575 + Azacitidine
for Acute Myeloid Leukemia
This trial is testing a new drug (APG-2575) combined with an existing drug (Azacitidine) to treat certain blood cancers that have not responded to other treatments. The goal is to see if this combination can more effectively kill cancer cells.
Recruiting1 award Phase 1 & 23 criteria
CC-96191
for Acute Myeloid Leukemia
This Phase 1, clinical study of CC-96191 will explore the safety, tolerability and preliminary biological and clinical activity of CC-96191 as a single-agent in the setting of Relapsed or refractory acute myeloid leukemia (R/R AML). The dose escalation (Part A) of the study will explore escalating intravenous doses of CC-96191 to estimate the MTD and/or RP2D of CC-96191 as monotherapy. The expansion (Part B), will further evaluate the safety and efficacy of CC-96191 administered at or below the MTD in one or more expansion cohorts in order to determine the RP2D.
Recruiting1 award Phase 16 criteria
More about Daniel Egan, MD
Clinical Trial Related3 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Daniel Egan, MD has experience with
- CC-96191
- CC-95266
- CYNK-001
- APG-2575
- Tamibarotene
- Azacitidine
Breakdown of trials Daniel Egan, MD has run
Acute Myeloid Leukemia
Leukemia
Myelodysplastic Syndrome
Multiple Myeloma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Daniel Egan, MD specialize in?
Daniel Egan, MD focuses on Acute Myeloid Leukemia and Leukemia. In particular, much of their work with Acute Myeloid Leukemia has involved Stage II patients, or patients who are Stage I.
Is Daniel Egan, MD currently recruiting for clinical trials?
Yes, Daniel Egan, MD is currently recruiting for 5 clinical trials in Seattle Washington. If you're interested in participating, you should apply.
Are there any treatments that Daniel Egan, MD has studied deeply?
Yes, Daniel Egan, MD has studied treatments such as CC-96191, CC-95266, CYNK-001.
What is the best way to schedule an appointment with Daniel Egan, MD?
Apply for one of the trials that Daniel Egan, MD is conducting.
What is the office address of Daniel Egan, MD?
The office of Daniel Egan, MD is located at: Swedish Cancer Institute, Seattle, Washington 98104 United States. This is the address for their practice at the Swedish Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.